Hepatitis E vaccine recombinant - Changchun Institute of Biological Products

Drug Profile

Hepatitis E vaccine recombinant - Changchun Institute of Biological Products

Latest Information Update: 20 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Changchun Institute of Biological Products
  • Developer Changchun Institute of Biological Products; Jiangsu Provincial Center for Disease Control and Prevention
  • Class Synthetic vaccines; Viral hepatitis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis E

Most Recent Events

  • 20 Sep 2016 Jiangsu Province Centers for Disease Control and Prevention in collaboration with Changchun Institute of Biological Products complete a phase I clinical trial in Hepatitis E (Prevention) in China (Parenteral) (NCT02603055)
  • 01 Jul 2015 Phase-I clinical trials in Hepatitis E (Prevention) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top